Clinical-stage ophthalmic biopharmaceutical company developing microdose therapeutics for eye diseases.
Eyenovia, Inc., headquartered in New York, New York, is an innovative clinical stage ophthalmic company specializing in developing therapeutics based on its proprietary microdose array print platform technology. The company is dedicated to advancing clinical microdosing of ophthalmic pharmaceutical agents through its Optejet branded targeted ocular delivery system.
Eyenovia focuses its efforts on developing treatments for specific ophthalmic conditions, including progressive myopia and age-related near vision impairment (presbyopia). The company's portfolio includes MicroLine, currently in a Phase III clinical development program aimed at improving near vision for individuals with presbyopia. Additionally, MicroPine is another Phase III candidate targeting pediatric myopia progression (near-sightedness), addressing a significant medical need.
Furthermore, Eyenovia is advancing MydCombi through Phase III clinical development, focusing on pharmaceutical mydriasis to facilitate eye exams with pupil dilation. These product candidates underscore Eyenovia's commitment to enhancing treartment options and improving outcomes for patients across various ophthalmic conditions.
In pursuit of its global strategy, Eyenovia has established strategic partnerships. This includes a licensing agreement with Bausch Health Ireland Limited for the development and commercialization of MicroPine in the United States and Canada, as well as a partnership with Arctic Vision (Hong Kong) Limited for MicroPine and MicroLine in China and South Korea. With a foundation in cutting-edge technology and a focus on targeted ocular delivery, Eyenovia continues to innovate in the field of ophthalmology, aiming to address unmet medical needs and improve vision care worldwide.